Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

Preclinical models of germline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) that reflect different clinical time points along the response spectrum of platinum/PARP inhibitor treatment were developed and used to evaluate mechanisms of resistance to these therapies.